EXELIXIS, INC.

EXEL

Real-time Estimate - 05/26 02:05:45 pm
18.285USD	+2.67%

Turn to zoom

Prev.	17.8100
Open	17.7800
High	18.5900
Low	17.7000
Volume	1 165 444

05/17	Transcript : Exelixis, Inc. Presents at RBC Capital Markets Global...
05/11	Transcript : Exelixis, Inc. Presents at Bank of America 2022 Healthcare...
05/10	Transcript : Exelixis, Inc., Q1 2022 Earnings Call, May 10, 2022
05/10	Exelixis Q1 Non-GAAP EPS, Revenue Higher; Reiterates 2022 Guidance

	Short Term	Mid-Term	Long Term
Trend	Bearish	Neutral	Neutral
Resistance	20,3	23,2	23,4
Spread/Res.	-12%	-23%	-24%
Spread/Supp.	2,1%	12%	12%
Support	17,4	15,8	15,8

Sales 2022	1 587 M - -
Net income 2022	291 M - -
Net cash 2022	1 276 M - -
P/E ratio 2022	19,9x
Yield 2022	-

Capitalization	5 712 M 5 712 M -
EV / Sales 2022	2,80x
EV / Sales 2023	2,29x
Nbr of Employees	954
Free-Float	97,7%

Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is...

>> Read more

Sector :

Bio Therapeutic Drugs

Calendar :

2022-05-25 Shareholder meeting

Trading Rating :

Investor Rating :

Sell Buy
Mean consensus	OUTPERFORM
Number of Analysts	14
Last Close Price	17,81 $
Average target price	26,45 $
Spread / Average Target	48,5%